ozanimod vs Siponimod (Mayzent)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Sclerosis

Shared mechanism: S1P receptor · full Multiple Sclerosis pipeline

ozanimod · Zeposia

Marketed by Bristol-Myers Squibb and partners

Approved in Multiple SclerosisSmall molecule (S1P1,5 modulator)
Partial signal

NCT01628393 · Phase 2/3 · completed

The trial was randomized, placebo-controlled and fully blinded in 258 participants, and both ozanimod doses significantly reduced new brain lesions on MRI versus placebo. Because the primary measure was an imaging biomarker rather than a clinical outcome such as relapse rate or disability, this trial supports but does not on its own confirm a clinical benefit.

Next expected readout: August 2028 · NCT06529406 (registry estimate)

Reported efficacy

Adjusted Annualized Relapse Rate (ARR) at the End of Month 24: Adjusted annualized relapse rate (ARR) over 24 months (RADIANCE): 0.17 ozanimod 1.0mg, 0.22 ozanimod 0.5mg, vs 0.28 interferon beta-1a; rate ratio vs interferon 0.62 (p<0.0001) for the 1.0mg dose and 0.79 (p=0.0167) for the 0.5mg dose (met)

Result source: NCT02047734

Siponimod (Mayzent)

Marketed by Novartis

Approved in Multiple Sclerosissmall molecule
Weak signal

NCT03623243 · Phase 3 · completed

The study was an open-label, single-arm trial with 185 participants and no placebo or active comparator, so its findings are descriptive rather than a controlled comparison. Its primary clinical endpoint was the number of participants with treatment-emergent adverse events related to siponimod; 59 participants were reported with such an event, but no comparative significance test was applicable.

Reported efficacy

Percentage of Participants With 3-month Confirmed Disability Progression (CDP) Events as Measured by the Expanded Disability Status Scale (EDSS) (Baseline, every 3 month up to the maximum of approximately 3 years): EXPAND (n=1,651), primary endpoint 3-month confirmed disability progression on EDSS: 26.3% with siponimod vs 31.7% with placebo; HR 0.79 (95% CI 0.65 to 0.95), Cox model p=0.0134 (CT.gov posted results). (met)

Result source: NCT01665144

Results for Multiple Sclerosis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointozanimodSiponimod (Mayzent)
Annualised relapse rate0.2 vs 0.3vs Interferon Beta-1a1 mg · wk 96 · n 433NCT02047734
5 other results
  • 0.2 vs 0.3 1 mg · wk 52 · n 447 · Phase 3 · primary NCT02294058
  • 0.2 vs 0.3 0.5 mg · wk 96 · n 439 · Phase 3 · primary NCT02047734
  • 0.2 vs 0.3 0.5 mg · wk 52 · n 451 · Phase 3 · primary NCT02294058
  • 0.2 vs 0.5 1 mg · wk 24 · n 83 · Phase 2/3 · secondary NCT01628393
  • 0.3 vs 0.5 0.5 mg · wk 24 · n 87 · Phase 2/3 · secondary NCT01628393
—Trial running · NCT04926818
Free of 3-month confirmed disability progression (%)—Trial running · NCT06408259—Trial running · NCT04926818
New or enlarging T2 lesions0.8 vs 9−8.2 vs placebo1 mg · wk 24 · n 83NCT01628393
1 other result
  • 1.4 vs 9 0.5 mg · wk 24 · n 87 · Phase 2/3 · secondary NCT01628393
—Trial running · NCT04926818

Annualised relapse rate

ozanimod
0.2 vs 0.3vs Interferon Beta-1a1 mg · wk 96 · n 433NCT02047734
5 other results
  • 0.2 vs 0.3 1 mg · wk 52 · n 447 · Phase 3 · primary NCT02294058
  • 0.2 vs 0.3 0.5 mg · wk 96 · n 439 · Phase 3 · primary NCT02047734
  • 0.2 vs 0.3 0.5 mg · wk 52 · n 451 · Phase 3 · primary NCT02294058
  • 0.2 vs 0.5 1 mg · wk 24 · n 83 · Phase 2/3 · secondary NCT01628393
  • 0.3 vs 0.5 0.5 mg · wk 24 · n 87 · Phase 2/3 · secondary NCT01628393
Siponimod (Mayzent)
—Trial running · NCT04926818

Free of 3-month confirmed disability progression (%)

ozanimod
—Trial running · NCT06408259
Siponimod (Mayzent)
—Trial running · NCT04926818

New or enlarging T2 lesions

ozanimod
0.8 vs 9−8.2 vs placebo1 mg · wk 24 · n 83NCT01628393
1 other result
  • 1.4 vs 9 0.5 mg · wk 24 · n 87 · Phase 2/3 · secondary NCT01628393
Siponimod (Mayzent)
—Trial running · NCT04926818
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Siponimod (Mayzent)
EXPAND (n=1,651), primary endpoint 3-month confirmed disability progression on EDSS: 26.3% with siponimod vs 31.7% with placebo; HR 0.79 (95% CI 0.65 to 0.95), Cox model p=0.0134 (CT.gov posted results). NCT01665144 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. ozanimod: 4 of 4 rows · Siponimod (Mayzent): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricozanimodSiponimod (Mayzent)
Dropout rate
—1.0 mga
NCT01628393 · Phase 2/3
show 11 more results
1.2%1 mg
NCT01628393 · Phase 2/3
—1.0 mg
NCT01628393 · Phase 2/3
—0.5 mg
NCT01628393 · Phase 2/3
2.3%0.5 mg
NCT01628393 · Phase 2/3
—0.5 mg
NCT01628393 · Phase 2/3
10.6%1 mg
NCT02047734 · Phase 3
15.6%0.5 mg
NCT02047734 · Phase 3
6.5%1 mg
NCT02294058 · Phase 3
5.8%0.5 mg
NCT02294058 · Phase 3
20.9%1.0 mg
NCT02576717 · Phase 3 · registry result, not featured evidence
21%0.5 mg
NCT02576717 · Phase 3 · registry result, not featured evidence
21.1%a
NCT03623243 · Phase 3
Discontinued due to AEs
—1.0 mga
NCT01628393 · Phase 2/3
show 11 more results
—1 mg
NCT01628393 · Phase 2/3
—1.0 mg
NCT01628393 · Phase 2/3
—0.5 mg
NCT01628393 · Phase 2/3
—0.5 mg
NCT01628393 · Phase 2/3
—0.5 mg
NCT01628393 · Phase 2/3
3%1 mg
NCT02047734 · Phase 3
2.9%0.5 mg
NCT02047734 · Phase 3
2.9%1 mg
NCT02294058 · Phase 3
1.6%0.5 mg
NCT02294058 · Phase 3
3%1.0 mg
NCT02576717 · Phase 3 · registry result, not featured evidence
3.7%0.5 mg
NCT02576717 · Phase 3 · registry result, not featured evidence
8.1%a
NCT03623243 · Phase 3
Serious AEs
7.3%1.0 mga
NCT01628393 · Phase 2/3
show 11 more results
—1 mg
NCT01628393 · Phase 2/3
0%1.0 mg
NCT01628393 · Phase 2/3
7.9%0.5 mg
NCT01628393 · Phase 2/3
—0.5 mg
NCT01628393 · Phase 2/3
3.4%0.5 mg
NCT01628393 · Phase 2/3
6.5%1 mg
NCT02047734 · Phase 3
7.1%0.5 mg
NCT02047734 · Phase 3
2.9%1 mg
NCT02294058 · Phase 3
3.5%0.5 mg
NCT02294058 · Phase 3
15.5%1.0 mg
NCT02576717 · Phase 3 · registry result, not featured evidence
15.7%0.5 mg
NCT02576717 · Phase 3 · registry result, not featured evidence
4.9%a
NCT03623243 · Phase 3
Most frequent reported AEs
1.0 mga
nasopharyngitis 13.8% (placebo 13.6%)
alanine aminotransferase increased 9.8% (placebo 0%)
upper respiratory tract infection 8.9% (placebo 3.4%)
NCT01628393 · Phase 2/3
show 9 more results
1.0 mg
gamma-glutamyltransferase increased 6% (placebo 0%)
nasopharyngitis 6% (placebo 13.6%)
alanine aminotransferase increased 4.8% (placebo 0%)
NCT01628393 · Phase 2/3
0.5 mg
upper respiratory tract infection 15.9% (placebo 3.4%)
nasopharyngitis 13.5% (placebo 13.6%)
gamma-glutamyltransferase increased 8.7% (placebo 0%)
NCT01628393 · Phase 2/3
0.5 mg
nasopharyngitis 12.6% (placebo 13.6%)
urinary tract infection 6.9% (placebo 2.3%)
back pain 5.7% (placebo 10.2%)
NCT01628393 · Phase 2/3
1 mg
nasopharyngitis 15.7%
headache 10.1%
upper respiratory tract infection 7.8%
NCT02047734 · Phase 3
0.5 mg
nasopharyngitis 13.4%
headache 12.5%
upper respiratory tract infection 8.2%
NCT02047734 · Phase 3
1 mg
headache 7.6%
nasopharyngitis 6.7%
upper respiratory tract infection 4%
NCT02294058 · Phase 3
0.5 mg
nasopharyngitis 9.7%
upper respiratory tract infection 6.8%
headache 6%
NCT02294058 · Phase 3
1.0 mg
nasopharyngitis 20.9% (placebo 13.5%)
headache 17% (placebo 5.4%)
covid-19 16.1% (placebo 21.6%)
NCT02576717 · Phase 3 · registry result, not featured evidence
0.5 mg
nasopharyngitis 21% (placebo 13.5%)
headache 16.9% (placebo 5.4%)
covid-19 15.5% (placebo 21.6%)
NCT02576717 · Phase 3 · registry result, not featured evidence
a
headache 13.5%
urinary tract infection 8.6%
nausea 8.1%
NCT03623243 · Phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

ozanimod

Gadolinium Enhancing Lesion 1.5 vs 11.1 placebo lesions @ 24wk1 mg
event count · lesions
NCT01628393 · Phase 2/3
show 7 more results
0.2 vs 3.2 placebo lesions @ 24wk1 mg
NCT01628393 · Phase 2/3
0.176 vs 0.373 Interferon Beta-1a lesions @ 96wk1 mg
NCT02047734 · Phase 3
0.16 vs 0.433 Interferon Beta-1a lesions @ 52wk1 mg
NCT02294058 · Phase 3
1.9 vs 11.1 placebo lesions @ 24wk0.5 mg
NCT01628393 · Phase 2/3
0.4 vs 3.2 placebo lesions @ 24wk0.5 mg
NCT01628393 · Phase 2/3
0.197 vs 0.373 Interferon Beta-1a lesions @ 96wk0.5 mg
NCT02047734 · Phase 3
0.287 vs 0.433 Interferon Beta-1a lesions @ 52wk0.5 mg
NCT02294058 · Phase 3
New or Enlarging T2 Lesion 0.8 vs 9 placebo lesions @ 24wk1 mg
event count · lesions
NCT01628393 · Phase 2/3
show 1 more result
1.4 vs 9 placebo lesions @ 24wk0.5 mg
NCT01628393 · Phase 2/3
Annualized Relapse 0.24 vs 0.5 placebo per year @ 24wk1 mg
event rate · per year
NCT01628393 · Phase 2/3
show 5 more results
0.172 vs 0.276 Interferon Beta-1a per year @ 96wk1 mg
NCT02047734 · Phase 3
0.181 vs 0.35 Interferon Beta-1a per year @ 52wk1 mg
NCT02294058 · Phase 3
0.35 vs 0.5 placebo per year @ 24wk0.5 mg
NCT01628393 · Phase 2/3
0.218 vs 0.276 Interferon Beta-1a per year @ 96wk0.5 mg
NCT02047734 · Phase 3
0.241 vs 0.35 Interferon Beta-1a per year @ 52wk0.5 mg
NCT02294058 · Phase 3
New or Enlarging T2 Lesion 1.835 vs 3.183 Interferon Beta-1a lesions/scan @ 96wk1 mg
event count · lesions/scan
NCT02047734 · Phase 3
show 1 more result
2.092 vs 3.183 Interferon Beta-1a lesions/scan @ 96wk0.5 mg
NCT02047734 · Phase 3
Time to 3m Confirmed Disability Worsening NA vs NA Interferon Beta-1a months1 mg
time to event · months
NCT02047734 · Phase 3
show 3 more results
NA vs NA Interferon Beta-1a months1 mg
NCT02294058 · Phase 3
NA vs NA Interferon Beta-1a months0.5 mg
NCT02047734 · Phase 3
NA vs NA Interferon Beta-1a months0.5 mg
NCT02294058 · Phase 3
Time to 6m Confirmed Disability Worsening NA vs NA Interferon Beta-1a months1 mg
time to event · months
NCT02047734 · Phase 3
show 3 more results
NA vs NA Interferon Beta-1a months1 mg
NCT02294058 · Phase 3
NA vs NA Interferon Beta-1a months0.5 mg
NCT02047734 · Phase 3
NA vs NA Interferon Beta-1a months0.5 mg
NCT02294058 · Phase 3
MRI Gadolinium Lesion-Free 65.6% (n=433) vs 56.2% (n=441) Interferon Beta-1a @ 96wk1 mg
responder rate · % of participants
NCT02047734 · Phase 3
show 3 more results
74.05% (n=447) vs 63.17% (n=448) Interferon Beta-1a @ 52wk1 mg
NCT02294058 · Phase 3
63.3% (n=439) vs 56.2% (n=441) Interferon Beta-1a @ 96wk0.5 mg
NCT02047734 · Phase 3
68.29% (n=451) vs 63.17% (n=448) Interferon Beta-1a @ 52wk0.5 mg
NCT02294058 · Phase 3
no New or Enlarged T2 Lesion 23.8% (n=433) vs 18.4% (n=441) Interferon Beta-1a @ 96wk1 mg
responder rate · % of participants
NCT02047734 · Phase 3
show 1 more result
23.5% (n=439) vs 18.4% (n=441) Interferon Beta-1a @ 96wk0.5 mg
NCT02047734 · Phase 3
Whole Brain Volume -0.707% (n=390) vs -0.937% (n=397) Interferon Beta-1a @ 96wk1 mg
percent change · % of baseline
NCT02047734 · Phase 3
show 3 more results
-0.69% (n=271) vs -0.94% (n=279) Interferon Beta-1a @ 96wk1 mg
NCT02047734 · Phase 3
-0.707% (n=398) vs -0.937% (n=397) Interferon Beta-1a @ 96wk0.5 mg
NCT02047734 · Phase 3
-0.71% (n=274) vs -0.94% (n=279) Interferon Beta-1a @ 96wk0.5 mg
NCT02047734 · Phase 3
MSFC -0.01 vs -0.052 Interferon Beta-1a Z-score @ 96wk1 mg
absolute change · Z-score
NCT02047734 · Phase 3
show 3 more results
0.003 vs -0.022 Interferon Beta-1a Z-score @ 52wk1 mg
NCT02294058 · Phase 3
0.036 vs -0.052 Interferon Beta-1a Z-score @ 96wk0.5 mg
NCT02047734 · Phase 3
-0.007 vs -0.022 Interferon Beta-1a Z-score @ 52wk0.5 mg
NCT02294058 · Phase 3
New or Enlarging T2 Lesion 1.465 vs 2.836 Interferon Beta-1a T2 lesions/scan @ 52wk1 mg
event count · T2 lesions/scan
NCT02294058 · Phase 3
show 1 more result
2.139 vs 2.836 Interferon Beta-1a T2 lesions/scan @ 52wk0.5 mg
NCT02294058 · Phase 3
MRI T2 Lesion-Free 27.96% (n=447) vs 23.44% (n=448) Interferon Beta-1a @ 52wk1 mg
responder rate · % of participants
NCT02294058 · Phase 3
show 1 more result
26.39% (n=451) vs 23.44% (n=448) Interferon Beta-1a @ 52wk0.5 mg
NCT02294058 · Phase 3

+ 23 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ozanimod's landscape · Siponimod (Mayzent)'s landscape